Auxilium Pharmaceuticals, Inc. was founded in 1999 and is headquartered in Malvern, Pennsylvania. Auxilium Pharmaceuticals, Inc. is a specialty biopharmaceutical company with a focus on developing and marketing products to urologists, endocrinologists, orthopedists and select primary care physicians. The Company’s product, Testim, is a topical 1% testosterone once-a-day gel indicated for the treatment of hypogonadism. Hypogonadism is defined as reduced or absent secretion of testosterone which can lead to symptoms such as low energy, loss of libido, adverse changes in body composition, irritability and poor concentration. The product pipeline of the Company includes XIAFLEX (clostridial collagenase for injection) for the treatment of Dupuytren’s contracture (Dupuytren’s), XIAFLEX for the treatment of Peyronie’s disease (Peyronie’s), XIAFLEX for the treatment of Adhesive Capsulitis (frozen shoulder syndrome), AA4010, treatment for overactive bladder using the transmucosal film delivery system and fentanyl pain product using the transmucosal film delivery system.

Helicos BioSciences Corporation was founded in 2003 and is headquartered in Cambridge, Massachusetts. Helicos BioSciences Corporation (Helicos) is a life sciences company focused on genetic analysis technologies for the research, drug discovery and clinical diagnostics markets. Helicos has developed a technology, called the True Single Molecule Sequencing (tSMS) technology, to facilitate the rapid analysis of large quantities of genetic material by directly sequencing single molecules of deoxyribonucleic acid (DNA) or single DNA copies of ribonucleic acid (RNA). The Company's Helicos Genetic Analysis Platform obtains sequencing information by repetitively performing a cycle of biochemical reactions on individual DNA molecules and imaging the results after each cycle. It consists of an instrument called the HeliScope Single Molecule Sequencer, an image analysis computer tower called the HeliScope Analysis Engine, associated reagents, which are chemicals used in the sequencing process, and disposable supplies.

Targeted Genetics is putting the bull's-eye on disease. The drug developer is working in the promising (though as yet unproven) field of gene therapies, drugs that deliver particular DNA sequences into targeted cells to encourage (or sometimes inhibit) the production of proteins associated with disease. The company's drug candidates -- targeting conditions such as retinal dystrophies, lateral sclerosis, HIV/AIDS, heart failure, and Huntington's disease -- employ proprietary technology using bio-engineered viral cells (called vectors) to deliver the genes. The company is working on its own to develop therapies for certain candidates and with development partners on some other programs.

Tridelta specialises in the development, manufacturing and marketing of diagnostic products for the animal health care industry. The company has commercialised five technologies to date with its "PHASE" range of Acute Phase Protein Assays, which are indicators of the presence of an inflammatory reaction, detected in the blood before the animal shows any physical signs of ill health. Species of specific interest include: cattle, horses, sheep, cats, dogs, pigs and rodents.

Santa Cruz, California might be known for its sun-baked bodies; Santa Cruz Biotechnology is known for its antibodies. The company makes antibodies used by researchers to identify and treat a variety of conditions. Its products include growth factor antibodies, steroid receptor antibodies, and tumor suppressor antibodies. The company also offers more than 10,000 target-specific small interfering RNA (siRNA), which are used to silence genes. Its siRNAs are designed to silence tumors suppressor proteins, cell cycle proteins, and lymphocyte signaling proteins, among others. Santa Cruz Biotechnology has offices in California, Japan, and Germany and sells its products through distributors worldwide.

Ipsen develops pharmaceutical products that target oncology, endocrinology, and neuromuscular disorders. The group additionally markets products to treat gastroenterology, cardiovascular, and cognitive disorders. Ipsen operates research-and-development (R&D) centers in Paris, Boston, Barcelona, and London, which have churned out more than 20 products to the global therapeutic market. Its R&D efforts focus on peptide engineering, protein engineering, medicinal chemistry, and advanced drug delivery. The company markets its products directly as well as through third parties, and has formed strategic development alliances with the likes of Medicis and Applied Biosystems (now part of Life Technologies Corporation).

AXM Pharma, Inc. is a global pharmaceutical company engaged in the production, marketing and distribution of pharmaceutical products in China. The Company produces, markets and distributes medicines in various dosages and forms in areas of medicinal treatment, as well as herbal remedies, vitamins and adjunctive therapies. Through its wholly owned subsidiary, AXM Pharma Shenyang, Inc., the Company has established a pharmaceutical operation focused on supplying the drugs and branded products in specific categories. Werke Pharmaceuticals, Inc. is the Company’s wholly owned subsidiary, which owns 100% of AXM Pharma Shenyang Inc., a wholly foreign owned enterprise (WFOE). Its product portfolio includes Asarone injectibles solution, Weifukang and Lifupeng. Weifukang is an antiseptic cream for cleansing acne and for relieving the symptoms of eczema, psoriasis and other skin irritations, such as contact dermatitis. Lifupeng (Rifampicin) is used for treatment of tuberculosis.

Repligen Corporation was founded in 1981 and is headquartered in Waltham, Massachusetts. Repligen Corporation develops novel therapeutics primarily for the treatment of diseases of the central nervous system. The company offers Protein A products, which are used in the production and purification of therapeutic monoclonal antibodies. Repligen also licenses its patent covering the use of CTLA4-Ig, a regulator of the activity of the immune system, and receives royalties from Bristol-Myers Squibb based on their U.S. Sales of Orencia. The company's development stage products include RG1068, human secretin for improved MRI of the pancreas; RG2417, uridine for bipolar depression; HDAC inhibitors for Friedreich's ataxia; and RG-SMA for spinal muscular atrophy. The company sells its Protein A products primarily through value-added resellers, as well as through distributors internationally.

Elite Pharmaceuticals, Inc. (Elite) is a specialty pharmaceutical company principally engaged in the development and manufacture of oral, controlled-release products. The Company’s activity includes improving off-patent drug products for life cycle management and developing generic versions of controlled-release drug products. Its technology is applicable to develop delayed, sustained or targeted-release pellets, capsules, tablets, granules and powders. As of March 31, 2009, the Company had two products, Lodrane 24 and Lodrane 24D, being sold commercially, and a pipeline of five additional drug candidates under active development in the therapeutic areas that include pain management, allergy and infection. Of the products under development, ELI-216, a once-a-day, abuse-deterrent oxycodone product, and ELI-154, a once-a-day oxycodone product, are in clinical trials, and Elite has completed pilot studies on two of its other generic product candidates.

Advanced Cell Technology, Inc. is a biotechnology company focused on developing and commercializing human embryonic and adult stem cell technology in the field of regenerative medicine. The Company has acquired, developed and maintain a portfolio of patents and patent applications that form the base for its research and development efforts in the area of embryonic and adult stem cell research. The Company’s technology base, in combination with its know-how, provides an advantage and will facilitate the successful development and commercialization of products for use in treatment of an array of chronic degenerative diseases and in regenerative repair of acute disease, such as trauma, myocardial infarction and burns. The Company’s embryonic stem (ES) cell research programs are divided into three core categories: cellular reprogramming, reduced complexity program, and stem cell differentiation.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.